$CVKD
Cadrenal Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000121390024041014 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.212M $1.126M
YoY Change
% of Gross Profit
Research & Development $1.254M $629.0K
YoY Change 1244.02% 581.83%
% of Gross Profit
Depreciation & Amortization $470.00 $597.00
YoY Change -21.27% 214.21%
% of Gross Profit
Operating Expenses $2.467M $1.756M
YoY Change 140.37% -58.2%
Operating Profit -$2.467M -$1.756M
YoY Change 140.37% -58.2%
Interest Expense $73.64K $92.33K
YoY Change 2512.62%
% of Operating Profit
Other Income/Expense, Net $73.64K $92.33K
YoY Change 217.73% -90.51%
Pretax Income -$2.393M -$1.663M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.393M -$1.663M
YoY Change 138.58% -67.85%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.10
Diluted Earnings Per Share -$0.15 -$0.10
COMMON SHARES
Basic Shares Outstanding 16.01M shares 16.01M shares
Diluted Shares Outstanding 16.01M shares 16.01M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.037M $6.566M
YoY Change
Cash & Equivalents $5.037M $6.566M
Short-Term Investments
Other Short-Term Assets $406.3K $461.6K
YoY Change
Inventory
Prepaid Expenses $234.9K $293.8K
Receivables
Other Receivables
Total Short-Term Assets $5.444M $7.028M
YoY Change 54.68% 58.31%
LONG-TERM ASSETS
Property, Plant & Equipment $1.220K $1.690K
YoY Change -64.94% 105.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.792K $3.792K
YoY Change 0.0% 0.03%
Total Long-Term Assets $13.67K $20.40K
YoY Change -65.74% -52.33%
TOTAL ASSETS
Total Short-Term Assets $5.444M $7.028M
Total Long-Term Assets $13.67K $20.40K
Total Assets $5.457M $7.048M
YoY Change 53.33% 57.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $759.5K $400.4K
YoY Change 872.01% 234.85%
Accrued Expenses $696.6K $440.8K
YoY Change 156.0% 70.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.465M $856.3K
YoY Change 291.37% 113.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.465M $856.3K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.465M $856.3K
YoY Change 282.38% 105.45%
SHAREHOLDERS EQUITY
Retained Earnings -$19.13M -$16.73M
YoY Change 48.38% 40.77%
Common Stock $23.12M $22.93M
YoY Change 197135.45% 195487.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.992M $6.192M
YoY Change
Total Liabilities & Shareholders Equity $5.457M $7.048M
YoY Change 53.33% 57.26%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$2.393M -$1.663M
YoY Change 138.58% -67.85%
Depreciation, Depletion And Amortization $470.00 $597.00
YoY Change -21.27% 214.21%
Cash From Operating Activities -$1.529M -$1.836M
YoY Change 29.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $298.00
YoY Change -99.99%
NET CHANGE
Cash From Operating Activities -1.529M -$1.836M
Cash From Investing Activities
Cash From Financing Activities 0.000 $298.00
Net Change In Cash -1.529M -$1.836M
YoY Change -145.95%
FREE CASH FLOW
Cash From Operating Activities -$1.529M -$1.836M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41596
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CADRENAL THERAPEUTICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0860746
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
822 A1A North
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 306
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Ponte Vedra
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32082
CY2024Q1 dei City Area Code
CityAreaCode
(904)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
300-0701
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
CVKD
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16008469 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6566418 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8402500 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
293767 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
89673 usd
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
167844 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
7028029 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8492173 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1690 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2287 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14920 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20998 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3792 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3792 usd
CY2024Q1 us-gaap Assets
Assets
7048431 usd
CY2023Q4 us-gaap Assets
Assets
8519250 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
400373 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
167319 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
440775 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
638206 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15167 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21350 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
856315 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
826875 usd
CY2024Q1 us-gaap Liabilities
Liabilities
856315 usd
CY2023Q4 us-gaap Liabilities
Liabilities
826875 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16008469 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16008469 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13022754 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13022754 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
16008 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
13022 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
22910811 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
22750768 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16734703 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15071415 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6192116 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7692375 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7048431 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8519250 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1125993 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
964732 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
629025 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3235317 usd
CY2024Q1 us-gaap Depreciation
Depreciation
597 usd
CY2023Q1 us-gaap Depreciation
Depreciation
190 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1755615 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4200239 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1755615 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4200239 usd
CY2024Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
92327 usd
CY2023Q1 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
3534 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
13567 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
216095 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-740139 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
92327 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-973335 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1663288 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5173574 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16008469 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10772493 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5551150 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5408575 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1140700 usd
CY2023Q1 cvkd Adjustmentsto Additional Paidin Capital Derecognitionofderivativeliabilities
AdjustmentstoAdditionalPaidinCapitalDerecognitionofderivativeliabilities
4596039 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
250000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
3000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
108276 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
286396 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5173574 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4065262 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7692375 usd
CY2024Q1 cvkd Adjustments To Additional Paid In Capital Issuance Of Investor Warrants
AdjustmentsToAdditionalPaidInCapitalIssuanceOfInvestorWarrants
298 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
162731 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1663288 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6192116 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1663288 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5173574 usd
CY2024Q1 us-gaap Depreciation
Depreciation
597 usd
CY2023Q1 us-gaap Depreciation
Depreciation
190 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
162731 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
286396 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13567 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
216095 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-740139 usd
CY2024Q1 cvkd Lessee Operating Non Cash Lease Expense
LesseeOperatingNonCashLeaseExpense
-105 usd
CY2023Q1 cvkd Lessee Operating Non Cash Lease Expense
LesseeOperatingNonCashLeaseExpense
89 usd
CY2023Q1 cvkd Issuance Of Shares To Settle Asset Purchase Agreement
IssuanceOfSharesToSettleAssetPurchaseAgreement
3000000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
204094 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
279912 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
167844 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-672295 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2196 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
233054 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-285330 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-197431 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-604944 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1836380 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1412794 usd
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
298 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
250000 usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
250000 usd
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5408575 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
298 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5408575 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1836082 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3995781 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8402500 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32586 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6566418 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4028367 usd
CY2023Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
3000000 usd
CY2023Q1 cvkd Derecognition Of Derivative Liabilitiy
DerecognitionOfDerivativeLiabilitiy
4596039 usd
CY2023Q1 cvkd Issuance Of Investor Warrants
IssuanceOfInvestorWarrants
108276 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1663288 usd
CY2024Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
163223 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1836380 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6566418 usd
CY2024Q1 cvkd Workings Capital
WorkingsCapital
6171714 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16734703 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of stock-based awards, deferred tax assets and valuation allowance, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash is maintained at high credit quality financial institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances are insured up to $250,000 at each financial institution. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidate, ability to obtain regulatory approval of its product candidate, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</p>
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
CY2024Q1 us-gaap Revenue Recognition Customer Acquisitions
RevenueRecognitionCustomerAcquisitions
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Acquisitions</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development (“IPR&amp;D”) asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR&amp;D asset to have an alternative future use: (a) the Company must reasonably expect that it will use the asset acquired in an alternative manner and anticipate economic benefit from that alternative use, and (b) the Company’s use of the asset acquired is not contingent on the further development of the asset subsequent to the acquisition date (that is, the asset can be used in an alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR&amp;D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.</p>
CY2024Q1 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3000000 usd
CY2024Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
6488507 usd
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.94
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
6488507 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
8287843 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
8287843 usd
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
79881 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4000 usd
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
209901 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
596131 usd
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
150993 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38075 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
440775 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
638206 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14920 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20998 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15167 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21350 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
15167 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
21350 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
6555 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
6636 usd
CY2024Q1 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
6696 usd
CY2023Q1 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
6501 usd
CY2024Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P7M
CY2024Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.12 pure
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
15623 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15623 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
456 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
15167 usd
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
7500000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7000000 usd
CY2023Q1 cvkd Net Proceeds From Issuanceof Common Stock
NetProceedsFromIssuanceofCommonStock
5408575 usd
CY2023Q1 cvkd Warrantto Purchase Common Stock Shares
WarranttoPurchaseCommonStockShares
84000 shares
CY2023Q1 us-gaap Shares Acquired Weighted Average Discount To Net Assets Percentage
SharesAcquiredWeightedAverageDiscountToNetAssetsPercentage
0.06 pure
CY2023Q1 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
6
CY2023Q1 cvkd Percentageof Public Offering Priceof Common Stock
PercentageofPublicOfferingPriceofCommonStock
1.20 pure
CY2023Q3 cvkd Combined Purchase Price Of Warrant
CombinedPurchasePriceOfWarrant
1.7499
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7500000 usd
CY2024Q1 cvkd Exercise Of Pre Funded Warrants Shares
ExerciseOfPreFundedWarrantsShares
2985715 usd
CY2024Q1 us-gaap Sale Of Stock Percentage Of Ownership After Transaction
SaleOfStockPercentageOfOwnershipAfterTransaction
0.0999 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
7660501 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
2985715 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
4674786 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2000000 shares
CY2024Q1 cvkd Stock Options Granted Shares Term
stockOptionsGrantedSharesTerm
P10Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1175000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.86
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M20D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
105000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1020000 shares
CY2024Q1 cvkd Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingGranted
P9Y9M18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2195000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.9
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y14D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
713058 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.8
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y5M4D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2195000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.9
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y14D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.87
CY2024Q1 cvkd Unrecognized Stock Based Compensation Expense
UnrecognizedStockBasedCompensationExpense
1151708 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
162731 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
286396 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1663288 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5173574 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16008469 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10772493 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6869786 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1376500 shares
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
usd
CY2024Q1 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
usd
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10772493 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16008469 shares
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2024Q1 cvkd Issuance Of Shares To Settle Asset Purchase Agreement
IssuanceOfSharesToSettleAssetPurchaseAgreement
usd
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
CY2024Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2024Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
CY2024Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
usd
CY2024Q1 cvkd Derecognition Of Derivative Liabilitiy
DerecognitionOfDerivativeLiabilitiy
usd
CY2024Q1 cvkd Issuance Of Investor Warrants
IssuanceOfInvestorWarrants
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
CY2024Q1 cvkd Share Based Compensation Arrangement By Share Based Payment Award Options Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
usd
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1 cvkd Weighted Average Remaining Contractual Life Years Exercised
WeightedAverageRemainingContractualLifeYearsExercised
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1 cvkd Weighted Average Remaining Contractual Life Years Canceled
WeightedAverageRemainingContractualLifeYearsCanceled
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P2Y
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10772493 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16008469 shares
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001937993

Files In Submission

Name View Source Status
0001213900-24-041014-index-headers.html Edgar Link pending
0001213900-24-041014-index.html Edgar Link pending
0001213900-24-041014.txt Edgar Link pending
0001213900-24-041014-xbrl.zip Edgar Link pending
cvkd-20240331.xsd Edgar Link pending
cvkd-20240331_cal.xml Edgar Link unprocessable
cvkd-20240331_lab.xml Edgar Link unprocessable
ea0205058-10q_cadrenal.htm Edgar Link pending
ea020505801ex31-1_cadrenal.htm Edgar Link pending
ea020505801ex31-2_cadrenal.htm Edgar Link pending
ea020505801ex32-1_cadrenal.htm Edgar Link pending
ea020505801ex32-2_cadrenal.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
ea0205058-10q_cadrenal_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cvkd-20240331_def.xml Edgar Link unprocessable
cvkd-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable